Data for investigational CD20xCD3 bispecific antibodies and new combination regimens with Polivy showed enhanced clinical benefits for people with non-Hodgkin lymphoma in early studies Basel, 4 June
F. Hoffmann-La Roche Ltd: European Commission approves Venclyxto-based combinations for adults with newly diagnosed acute myeloid leukaemia who are ineligible for intensive chemotherapy
leukaemia
azacitidine significantly improved overall survival in patients ineligible for intensive chemotherapy, a patient population who typically have a five-year overall survival rate of less than 10%
1
Venclyxto
-based combinations to provide clinically meaningful benefits in difficult to treat blood cancers
Basel, 25 May 2021 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the European Commission has approved Venclyxto (venetoclax) in combination with hypomethylating agents, azacitidine and decitabine, for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (AML) who are ineligible for intensive chemotherapy.
Pharma Stock Roundup: JNJ s Q1 Earnings & Sales Beat, RHHBY Sales, & Other Updates Zacks.com 2 hrs ago J&J JNJ announced strong first-quarter results, beating estimates for both earnings and sales.
Roche’s RHHBY COVID-19 diagnostics tests sales boosted the top line, offsetting declines in its core drug business. The FDA granted approval to
Glaxo’s GSK endometrial cancer therapy, Jemperli (dostarlimab).
Recap of the Week’s Most Important Stories
J&J Earnings & Sales Beat: J&J beat first-quarter estimates for earnings as well as sales. Its Pharmaceuticals unit continued to perform above market levels while the recovery in the Medical Devices unit continued. However, unfavorable comparisons to the year-ago quarter due to COVID-19 pantry loading and demand surges experienced in 2020 hurt sales of the Consumer Health segment in the first quarter of 2021
Roche witnessed a slight decrease in Q1 2021 pharmaceutical sales – a drop of 9% compared to the first three months of 2020 - as it faced continued biosimilars competition; the COVID-19 pandemic also played a role.
The company reported yesterday [April 21] that sales in its pharmaceutical division dipped 9% to CHF 10.6bn (US$11.54bn).
The pandemic also served to undermine the pharmaceutical division’s sales, especially for medicines where regular visits to hospitals or health practices are needed, such as infusions. Partly compensating that negativity, however, were the additional sales of medicines used to treat COVID-19, said Roche.
New medicines, those launched since 2012, grew by 20% and generated sales of CHF 5.2bn in the quarter, said the pharma giant.
By Olivia Bugault Roche Holding AG said Wednesday that sales slightly decreased in its first quarter, while it confirmed its outlook for the year. The Swiss pharmaceutical major posted sales of 14.93 billion Swiss francs ($16.30 billion), down from CHF15.14 billion a year earlier. At constant exchange rate, sales increased 3%, it said. An analysts consensus provided by FactSet had sales at CHF15.01 billion. Sales at its pharmaceuticals division its largest business fell to CHF10.6 billion from CHF12.26 billion, while it rose 55% at constant exchange rate at its diagnostic division, it said. The decline in sales at its pharmaceuticals business is mainly because of the coronavirus pandemic and the competition of biosimilars, Roche said. The impact of biosimilars on sales of the established cancer medicines MabThera/Rituxan, Avastin and Herceptin remained significant (combined sales reduction of CHF1.6 billion), especially in the U.S., it said.